Publications by authors named "Carole Hospital-Gustem"
Purpose Of The Report: We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma.
Methods: 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed.
Article Synopsis
- Two FDA-approved CAR T cell therapies, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), were studied in a retrospective analysis of 70 patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) to evaluate their usage, effectiveness, and safety.
- The study found overall response rates (ORRs) of 63% at 1 month and 45% at 3 months, with median progression-free survival (PFS) of 3.0 months and overall survival (OS) of 11.8 months, indicating significant but variable effectiveness across patients.
- Common side effects included cytokine release syndrome (CR